Recently, we reported on the associations of seven single nucleotide polymorphisms (SNPs) in the promoter region of MMP1 gene with susceptibility to cutaneous melanoma (CM). Considering the reported correlation between MMP1 expression and melanoma progression, we hypothesized that these promoter SNPs might affect CM progression and prognosis. In this study, we examined the associations of seven SNPs with overall survival, as well as six clinicopathological factors in 754 patients with CM. After adjustment for 11 covariates, we observed significant associations of the SNP -422A > T (rs475007) with ulceration status (P = 0.012), primary tumor thickness (P = 0.040), and anatomic site (P = 0.030). We also observed significant associations of the SNP -755T > G (rs498186) with ulceration status (P = 0.038) and anatomic site (P = 0.003). Two SNPs, -839G > A and -519A > G, were marginally associated with primary tumor thickness, ulceration status, and anatomic site. Furthermore, the frequency of haplotype 2G-G-G-A-A-G-T was higher in patients with ulceration (odds ratio = 2.18, 95% confidence interval: 1.08-4.40, P = 0.030) compared with those without ulceration. However, we did not find significant associations of these SNPs with overall survival and other clinical factors. As primary tumor thickness and ulceration status are two important indicators of tumor progression and have significant associations with melanoma prognosis, our results suggested that these promoter SNPs in MMP1 might have potential effects on melanoma progression and prognosis by influencing related clinical factors.
Introduction
Melanoma is the most aggressive form of skin cancer, and its incidence is increasing [1] . Melanoma progresses in two phases: the radial and vertical growth phases. The cure rate for melanoma in the radial growth phase is approximately 100% after surgery [2] . However, melanoma in the vertical growth phase is more aggressive and is able to metastasize. As few treatments are effective against advanced melanoma, the prognosis for it is poor. The 1-year survival rates were 33-62% in patients with distant metastatic melanoma [3] . Therefore, identification of predictive markers that distinguish high-risk melanoma cases is of great clinical importance.
Melanoma progression is a multiple-step process that involves many genes. Degradation of the extracellular matrix (ECM) and basement membrane barriers is a key step in this process. Researchers have shown that the matrix metalloproteinases (MMPs), a family of calciumdependent and zinc-dependent endopeptidases, are critical for ECM degradation [4] . To date, studies have identified at least 24 MMPs in humans [5] . They are classified into four groups on the basis of their substrate specificity and cellular location: collagenases, gelatinases, stromelysins, and membrane-associated MMPs. MMP1, one of the most widely expressed interstitial collagenases, plays a significant role in ECM degradation. The MMP1 gene is located on 11q22 and is expressed in various cells [6] . Previous studies have shown that an increased expression of MMP1 modulates melanoma development, progression, and metastasis [7] [8] [9] [10] . Specifically, patients with melanoma having increased expression of MMP1 have exhibited worse outcomes than patients having lower expression of it [11] .
It has been reported that the promoter region of the MMP1 gene contains binding sites for various transcription factors, such as AP-1, AP-2, and Ets/PEA-3, and response elements to glucocorticoids, retinoic acid, and cyclic adenosine monophosphate [12, 13] . Polymorphisms in this region may regulate MMP1 expression by influencing the binding of these transcription factors. The polymorphism of insertion/deletion of guanine at position -1607 has been found to have a role in the regulation of MMP1 expression by creating an Etsbinding site [14] . Groups have widely studied the association of this variation with risk of development or progression of various cancers [15] [16] [17] [18] . Specifically, -1607 1G/2G and six other single nucleotide polymorphisms (SNPs: -839G > A, -755T > G, -519A > G, -422A > T, -340A > G, and -320T > C) in the MMP1 promoter region exhibited haplotype effects on MMP1 promoter activity [19] . We recently reported the significant associations of several of these SNPs in the MMP1 promoter region with cutaneous melanoma (CM) susceptibility [20] . However, until now, little has been known about the correlation between these SNPs and melanoma progression and prognosis [21] . In this study, we investigated the association of these seven promoter SNPs with CM progression and prognosis in 754 CM patients with available genotyping and clinical data.
Materials and methods

Study patients
Recruitment of the study patients was described previously [20] . In brief, 754 patients with newly diagnosed, histologically confirmed, and untreated CM were recruited consecutively at The University of Texas MD Anderson Cancer Center from April 1994 to April 2008. A one-time blood sample (30 ml) was drawn from each study participant. Informed consent to participate in the study was obtained from the patients, and the study was approved by the MD Anderson Institutional Review Board.
Patients' clinicopathological information, including disease stage at diagnosis (based on the 2001 American Joint Committee on Cancer staging system), disease progression, and survival duration, was obtained. The main clinical factors used in this study included primary tumor thickness (Breslow), ulceration status, Clark level, anatomic site, sentinel lymph node status and stage at diagnosis [22] . In the analysis, tumor thickness was divided into three categories: thin (r 1 mm), intermediate (1.01-4.00 mm), and thick (> 4.00 mm) [3] . The five Clark levels of invasion were grouped into three categories: I, II-III, and IV-V. Considering melanomas on the extremities have better prognosis than those on the head, neck, or trunk (axial) [23] , we treated the primary CM anatomic site as a dichotomous variable: extremity (e.g. arm, hand, foot and leg) and axial (e.g. face, forehead, ear, cheek, nose, neck, eye, scalp, trunk, buttock, and groin).
Single nucleotide polymorphism selection and genotyping
The SNP selection method we used was described previously [20] . In brief, seven reported common (minor allele frequency Z 5%) SNPs in the MMP1 promoter
, and -320T > C [rs494379]) were selected for genotyping. These SNPs were not in linkage disequilibrium as reported previously [15, 20] .
The TaqMan genotyping method (Applied Biosystems, Foster City, California, USA) was used as described previously [20] with genomic DNA extracted from whole blood. Each 96-well plate had one positive control, one negative control, and five duplicate samples.
Statistical analysis
The w 2 -test and unconditional logistic regression analysis were used to evaluate the correlations between SNPs and the six clinicopathological factors for CM. The raw and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated with/without adjustment for the 11 covariates including age, sex, family history of any cancer in first-degree relatives, and the sunlight exposurerelated factors, including moles, dysplastic nevi, hair color, eye color, skin color, tanning ability, freckling in the sun as a child, and history of sunburn. In the survival analysis, deaths from any causes were treated as events, and living participants were censored at the time of the last contact. The overall survival was calculated from the date of diagnosis of CM till death or censorship. The association between each SNP and overall survival duration was estimated using the Kaplan-Meier method and the log-rank test. The hazard ratio and 95% CI were assessed in a Cox regression analysis with/without adjustment for sex, age, stage, primary tumor thickness, ulceration status, Clark level, and anatomic site. As sentinel lymph node biopsy was not performed in 248 patients (32.9%) with thin melanoma or in-situ melanoma, this clinical varible was not included in the Cox model. Haplotype analysis was carried out using SAS (Statistical Analysis System)/Genetics Module.
All statistical analyses were conducted using the SAS software (version 9.2; SAS Institute Inc., Cary, North Carolina, USA). Two-sided P values of less than 0.05 were considered statistically significant.
Results
The clinical and histological characteristics of the study population are shown in Table 1 . All of the participants were non-Hispanic white individuals. The final study population consisted of 490 male and 264 female patients. The age at diagnosis ranged from 21 to 84 years old (median = 54 years). At diagnosis, 79 patients had melanoma in situ, 567 had stage I-II CM (415 at stage I, 43 at stage I/II, and 109 at stage II), and 108 had stage III-IV CM (106 at stage III and two at stage IV). Table 2 , although none of the seven SNPs was significantly associated with primary tumor thickness in the univariate analysis, after adjustment for the 11 covariates, SNP -422A > T showed significant association with primary tumor thickness under the dominant genetic model (P = 0.04); and another SNP -839G > A showed marginally association with primary tumor thickness under the codominant model (P = 0.062; Table 2 ). In addition, more patients with thin tumors than with thick tumors were variant allele carriers of -839G > A (GA or AA genotype) and -422A > T (AT or TT genotype). Table 3 , SNP -422A > T showed significant association with ulceration status (P = 0.023 for codominant) in the univariate analysis. After adjustment for 11 covariates, two SNPs (-755T > G and -422A > T) had significant associations with the ulceration status under the dominant genetic model. Compared with wild-type homozygotes (TT genotype), variant allele carriers (TG or GG genotypes) of -755T > G had an OR of 1.85 (95% CI: 1.04-3.33, P = 0.038) for ulceration, whereas variant allele carriers (AT or TT genotypes) of -422A > T had an OR of 0.52 (95% CI: 0.31-0.86, P = 0.012) compared with the wild-type homozygotes (AA genotype). SNP -839G > A exhibited a marginally significant association with ulceration status (P = 0.055) under the dominant model. Table 4 showed the correlation results between MMP1 promoter SNPs and anatomic site. In the univariate analysis, significant association was found between SNP -755T > G and primary anatomic site (crude OR = 1.52, 95% CI: 1.11-2.07, P = 0.009 under the dominant model). After adjustment for 11 covariates, two SNPs were significantly associated with anatomic site (P = 0.003 for -755T > G under the dominant genetic model and P = 0.030 for -422A > T under the codominant genetic model). More patients with axial than with extremity CM were variant allele carriers of -755T > G (TG or GG genotype; 70.6 vs. 61.4%, adjusted OR = 1.67, 95% CI: 1.120-2.34). In addition, the SNP -519A > G was marginally associated with anatomic site (adjusted OR = 0.71, 95% CI: 0.51-0.99, P = 0.044 under the dominant model).
As shown in
We also performed a haplotype analysis to evaluate the joint effect of the seven SNPs on six clinical factors. There were seven haplotypes with frequencies greater than 0.05, and we combined the rest haplotypes into one group in this analysis ( Table 5 ). Compared with the most frequent haplotype G-A-T-G-T-A-T (the SNP order was -1607 1G/2G, -839G > A, -755T > G, -519A > G, -422A > T, -340A > G, and -320T > C), the frequency of haplotype 2G-G-G-A-A-G-T was significantly higher in CM patients with ulceration (adjusted OR = 2.18, 95% CI: 1.08-4.40, P = 0.030) compared with those without ulceration. No other significant associations were observed between haplotypes and other clinical phenotypes (data were not shown).
We also examined the association of these seven SNPs and their haplotypes with overall survival. The median follow-up time among all patients was 32.9 months (range: 0.8-364.1 months). Forty-six patients died during follow-up because of melanoma or other reasons. However, no SNPs and haplotypes showed significant effect on melanoma survival in the univariate and multivariate Cox regression analyses. We did not find that any SNPs in the MMP1 promoter region were significantly associated with Clark level, sentinel lymph node status, and melanoma stages either (data not shown).
Discussion
In this study, for the first time, we investigated the associations of seven promoter SNPs in MMP1 with six melanoma clinicopathological factors and overall survival.
Our results showed that four SNPs (-839G > A, -755T > G, -519A > G, and -422A > T) were associated with three clinical factors: primary tumor thick-ness, ulceration status, and anatomic site, although no significant association was observed between these SNPs and melanoma overall survival with only 46 deaths of 754 CM patients. Therefore, our results partially supported the hypothesis that MMP1 promoter SNPs might have potential effects on melanoma progression and prognosis by influencing these clinical factors.
Researchers have shown that -1607 1G/2G can regulate MMP1 expression [14] . The associations of this SNP with cancer progression and prognosis were not consistent among previous studies. For example, -1607 1G/2G was significantly associated with disease-free or overall survivals in patients with epithelial ovarian cancer [24] and colorectal cancer [13] . However, the significant association was not found in breast cancer [18] , esophageal adenocarcinoma [17] , and lung cancer [25] . In the present study, we did not observe significant association of this variant with melanoma overall survival and the six clinicopathological factors. This was consistent with one previous study [21] , which observed that this variant had no significant effect on melanoma disease-free survival, as well as primary tumor thickness and stage. These results may indicate a multilevel regulation of MMP1 expression during tumor progression. In addition to the promoter SNPs, it is known that other factors are involved in the regulation of MMP1 transcription, such as external stimuli and promoter methylation [26] [27] [28] [29] . Except for -1607 1G/2G, the effects of other promoter SNPs in MMP1 on cancer progression are little known. In our study, we observed -422A > T was associated with thinner melanoma and absence of ulceration, whereas -755T > G was associated with presence of ulceration. Although there are few functional studies for these two SNPs, in-silico prediction using TFSEARCH (http:// www.cbrc.jp/research/db/TFSEARCH.html) shows that the variant allele T in the position of -422 would abolish the binding site of human transcript factor USF, whereas the variant allele G in -755 could create a new binding site for p300 [30] . Further functional analysis may be warranted for the validation of these predictions.
A previous study demonstrated that seven promoter SNPs exerted a haplotype effect on the MMP1 promoter activity in cancer cells [19] . In the present study, we observed that the haplotype 2G-G-G-A-A-G-T was more frequent in CM patients with ulceration than patients without ulceration. This result was partially supported by the results of the aforementioned study [19] , in which this haplotype (reported as GG-G-G-A-T-C-T) and the haplotype 2G-G-G-A-T-A-T (identical to the reported GG-G-G-A-T-T-T) had significantly higher promoter activity than that of other haplotypes in the A2058 melanoma cell line. In our recent study, two MMP1 haplotypes (1G-A-G-A-T-G-T and 2G-G-G-A-T-A-T) were also significantly associated with an increased risk of CM [20] . Thus, both of our results are evidence that these seven promoter SNPs of MMP1 may jointly affect CM development and progression.
The correlations between abnormal expression of MMPs and melanoma progression have been evidenced in a number of studies [31] . However, previous studies on functional polymorphisms in MMP2, MMP3, and MMP9 did not provide strong evidence for the roles of these genes in melanoma progression [32, 33] . In this study, we also did not observe direct association between promoter SNPs in MMP1 and melanoma progression and clinical outcome, which indicated that these SNPs might just have moderate effects on melanoma progression. Future investigations on more other MMPs genes and their interactions may be helpful to better understand the genetic mechanism underlying melanoma progression and reveal new progression predictive biomarkers. For example, recently, one systematic mutation analysis of MMPs family found the mutation of MMP8 could facilitate melanoma progression [34] .
In conclusion, we observed significant associations of SNPs in the MMP1 promoter with three clinicopathological factors, and one common haplotype composed of seven promoter SNPs was over-represent among patients with ulceration. These findings provide evidence that potential functional SNPs in the MMP1 promoter may individually or jointly influence CM progression. Certainly, there are limitations in this study. First, because we have less patients with advanced stages, the number of outcome events was small (n = 46), which limited the power of our survival analysis. Second, we do not have the tumor tissues for MMP1 gene expression analysis to correlate with the SNP data. However, the analysis of the available SNPs in the MMP1 promoter region and its mRNA expression from 90 HapMap CEU cell lines showed a significant correlation for SNP -755T > G (rs498186) [35] . Although the expression data were obtained from human peripheral blood cells not tissue samples, the result might provide some functional evidence for our findings. Definitely, further validation of these results in a larger patient population, the functional significance of each of the promoter SNPs, and their correlation with gene expression levels in tissue samples are warranted to confirm the roles of these SNPs in melanoma progression. Recently available genomewide association studies may also provide great opportunities for us to further examine the effect of tagging SNPs in the entire MMP1 and other MMPs genes on CM risk and progression.
